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or bwo@umcg.nlAbstractEarly carbohydrate metabolism disorders (ECMDs) and diabetes mellitus (DM) are frequently
associated with acromegaly. We aimed to assess the prevalence of ECMDs in patients with
acromegaly and to compare the results with those in adults without acromegaly using two
population-based epidemiologic surveys. We evaluated 97 patients with acromegaly in
several phases of their disease (mean age, 56 years and estimated duration of acromegaly,
12.5 years). An oral glucose tolerance test was done in those not yet diagnosed with DM to
reveal asymptomatic DM or ECMDs (impaired glucose toleranceCimpaired fasting glucose).
Comparisons were made between patients with acromegaly and participants from the
general adult population (nZ435) and an adult population with multiple type 2 diabetes
risk factors (nZ314), matched for gender, age and BMI. DM was diagnosed in 51 patients
with acromegaly (52.5%) and 14.3% of the general population (P!0.001). The prevalence of
ECMDs was also higher in patients with acromegaly than in the general population and in
the high-risk group; only 22% of patients with acromegaly were normoglycaemic. The
prevalence of newly diagnosed ECMDs or DM was 1.3–1.5 times higher in patients with
acromegaly compared with the high-risk group. Patients with acromegaly having ECMDs or
DMwere older, more obese and had longer disease duration and higher IGF1 levels (Z-score).
Logistic regression showed that the severity of glucose derangement was predicted by age,
BMI and IGF1 levels. In patients with acromegaly, the prevalence of DM and ECMDs
considerably exceeds that of the general population and of a high-risk group, and







(2014) 3, 93–98IntroductionDisturbances of glucose metabolism are frequently
observed in patients with acromegaly. In one of the first
papers to be published on this topic, abnormal glucose
tolerance was found in over 60% of patients with
acromegaly (1). The glucose anomalies in these patients
are now known to include diabetes mellitus (DM),
impaired glucose tolerance (IGT) and impaired fasting
glucose (IFG) and have been discussed extensively in areview by Colao et al. (2). Looking more specifically at
early carbohydrate metabolism disorders (ECMDs) –
defined as IFG, IGT or their combination – its prevalence
in patients with acromegaly has been shown to vary
between 16 and 46% (3, 4, 5). While most epidemiological
studies have shown the prevalence of ECMDs to be higher
than that of overt diabetes (2, 5, 6, 7), not all studies report


















Research A V Dreval et al. Diabetes in acromegaly 2–6 3 :94and/or progression to diabetes in patients with acromegaly
may depend on several factors, such as age and gender (5),
the levels of growth hormone (GH) (9), as well as the
duration of acromegaly and duration of exposure to
elevated GH levels (9, 10). However, other authors have
found no differences in GH levels and insulin-like growth
factor 1 (IGF1) levels or disease duration between those
with glucose disturbances and those who were normo-
glycaemic (5, 6, 10, 11). A further possible factor involved
in the early development of diabetes is a positive family
history of DM (5, 12). A final factor that may also influence
the development of glucose disturbances is the specific
treatment for acromegaly. Somatostatin analogues may
influence glucose metabolism both by lowering insulin
secretion and by lowering GH and IGF1 levels (13, 14).
The aim of this study was to assess the prevalence of
ECMDs and DM in patients with acromegaly undergoing
treatment at a large tertiary referral centre in Moscow (15)
and to compare the results with the prevalence of
such glucose disturbances in adults without acromegaly
using two population-based surveys (16, 17). We also
analysed the factors contributing to the development of
hyperglycaemia.Table 1 Comparative characteristics of patients with acro-








Male/female (%) 16/84 13/87
Age (years) 56 (47.5–64.5) 56 (47–64)
BMI (kg/m2) 31.0 (27.7–34.2) 30.6 (27.2–34.1)
SBP (mmHg) 138G20 140G24
DBP (mmHg) 86G13 86G12
Known diabetes, n (%) 24 (24.7) 30 (6.9)
Newly diagnosed diabetes,
n (%)
27 (27.8) 32 (7.4)
Total diabetes, n (%) 51 (52.5) 62 (14.3)
Isolated IFG, n (%) 10 (10.3) 45 (10.3)
Isolated IGT, n (%) 4 (4.1) 14 (3.2)
Combination of IFGCIGT,
n (%)
11 (11.3) 23 (5.3)
ECMDs, n (%) 25 (25.8) 82 (18.8)
Normoglycaemia, n (%) 21 (21.6) 291 (66.9)
Data are given as absolute numbers (n) and percentage (%) or median
(interquartile range). Groups were matched according to gender, age and
BMI. SBP, systolic blood pressure; DBP, diastolic blood pressure; IFG,
impaired fasting glucose; IGT, impaired glucose tolerance; ECMDs, early
carbohydrate metabolism disorders.Subjects and methods
Patients
A total of 97 patients with acromegaly undergoing treat-
ment or long-term follow-up at the outpatient clinic of the
Moscow Regional Clinical Research State Institute under-
wentanextensiveevaluation,which includedmeasurement
of height, weight and blood pressure. Those patients who
had not previously been diagnosed with DM underwent
an oral glucose tolerance test (OGTT). In the fasting state,
and 30, 60, 90 and 120 min after oral administration of
75 g glucose, blood was drawn for the simultaneous
measurement of plasma levels of GH and glucose. In
patients, who had already been diagnosed with DM, GH
levels were measured in the fasting state and subsequently
every 30 min for 2 h. As hypopituitarism or treatment for
hypopituitarism can influence carbohydrate metabolism,
we did not include patients requiring such therapy.
The prevalence of disturbed glucose metabolism was
compared between patients with acromegaly and adults
without acromegaly using the results of two population-
based studies, during which study an OGTT was per-
formed. The first study was performed in 2006 among a
random sample of the adult population living in two
districts of theMoscow region, i.e. the Lukhovitsky districthttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0021
 2014 The authors
Published by Bioscientifica Ltdin the southeastern part of the Moscow Region (58 800
inhabitants) and the town of Zhukovsky (105 332 inhabi-
tants). The second study was performed between 2009 and
2010 among an adult population, who had a high risk of
developing type 2 diabetes (T2DM), living in three
different districts (Kashirsky, Mozhaisky and Kolomensky
districts) established with the FINDRISK questionnaire.
A risk score of 12 was selected as the cut-off point for
categorising a person at high risk for DM (18). For each
patient with acromegaly, up to five participants from both
screening studies were matched for age, gender and BMI.
ECMDs (IGT and IFG) and T2DM were diagnosed
according to the WHO recommendations (19).
The activity of acromegaly was assessed as described in
the 2009 international consensus statement (20). The
duration of acromegaly was estimated starting from when
the first complaints of specific changes in physical
appearance occurred.
The studies were approved by the Medical Ethical
Review Committee of the Moscow Regional Clinical
Research State Institute.Laboratory measurements
Serum concentrations of GH were measured by a two-site
IRMA (Immunotech SA, Prague, Czech Republic; intra-
assay variation, 0.6% and inter-assay variation, 13.5%),This work is licensed under a Creative Commons
Attribution 3.0 Unported License.







Number of patients/participants 73 325 314
Males/females (%) 19/81 15/85 15/85
Age (years) 54 (47–60) 54 (46–62) 54 (48–62)
BMI (kg/m2) 30.1 (26.9–34.0) 29.6 (26.5–33.9) 30.5 (27.2–35.1)
SBP (mmHg) 135G19 137G24 143G23
DBP (mmHg) 84G11 85G12 88G12
Newly diagnosed diabetes, n (%) 27 (37.0) 31 (9.5) 77 (24.5)
Isolated IFG, n (%) 10 (13.7) 36 (11.1) 32 (10.2)
Isolated IGT, n (%) 4 (5.5) 13 (4.0) 32 (10.2)
Combination of IFGCIGT, n (%) 11 (15.1) 11 (3.4) 21 (6.7)
ECMDs, n (%) 25 (34.2) 60 (18.5) 85 (27.1)
Normoglycaemia, n (%) 21 (28.8) 234 (72.0) 152 (48.4)
Data are given as absolute numbers (n) and percentage (%) or median (interquartile range). Groups were matched for gender, age and BMI. SBP, systolic


















Research A V Dreval et al. Diabetes in acromegaly 3–6 3 :95and levels of IGF1 were measured by an IRMA (Immuno-
tech SA; intra-assay variation, 7.1% and inter-assay
variation, 11.9%) using a Beckman Coulter device
(Beckman Coulter, Villepinte, France). Plasma glucose
levels were measured using a hexokinase method on a
























All statistical analyses were performed using IBM SPSS
Statistics, version 20 for Windows (IBM, Armonk, NY,
USA). Baseline characteristics were reported as mean and
interquartile range (IQR) for continuous variables and as
number and percentage for dichotomous variables. To
compare unpaired variables, the c2-test or Mann–Whitney
U test was used. The differences were considered statisti-
cally significant at P!0.05. Logistic regression analysis
using a multinomial logit model was used to identify
risk factors for diabetes or ECMDs. The independent
variables used in this analysis were age, BMI (continuous),
duration of acromegaly, fasting GH, IGF1, treatment with
an somatostatin analogue (SSA) (yes/no) and previous



















Prevalence of carbohydrate metabolism disturbance according to age in
patients with acromegaly and the general adult population.Results
The characteristics of patients with acromegaly are given
in Tables 1 and 2. The mean age of patients with
acromegaly was 56 years (IQR 47–64). Of the 97 patients,
81 were women, and the mean estimated duration of
acromegaly was 13 years (IQR 7–20). Patients were in
different phases of their disease: 16 patients had newlyhttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0021
 2014 The authors
Published by Bioscientifica Ltddiagnosed acromegaly, 38 subjects had previously under-
gone transsphenoidal surgery (TSS) and 65 were being
treated with an SSA, either directly after diagnosis (nZ40),
or because of persistent GH overproduction despite TSS
(nZ25). GH overproduction was controlled in 28 of the
97 individuals. None of the patients were treated with
a dopamine agonist or with pegvisomant.
In 24 patients with acromegaly, DM had previously
been diagnosed during the course of their disease. Out of
24, six were being treated with a diet only, six with oral
blood glucose lowering agents (either metformin or
sulphonylurea), two with insulin alone and ten with
insulin plus an oral agent (metformin or sulphonylurea).
In 27 of the 73 patients who underwent an OGTT, diabetes
was diagnosed, resulting in a total number of 51 (52.5%)
patients with DM. This prevalence was 3.5 times higher
than the prevalence of T2DM in the general populationThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 3 Characteristics of the different groups of patients with acromegaly according to disturbances of glucose metabolism.
Parameters NGT ECMDs DM P value
Number of patients 21 25 51 –
Male/female, n 7/14 4/21 5/46 0.050
Age (years) 47G12 53G12 60G11 !0.001
BMI (kg/m2) 28.4G2.8 31.2G5.4 33.1G5.8 0.009
SBP (mmHg) 131G21 132G16 144G21 0.014
DBP (mmHg) 83G12 82G11 89G13 0.061
Estimated duration of acromegaly (years) 9.0 (5.4–12.8) 11.0 (6.8–20.0) 15.0 (8.0–24.0) 0.013
Basal GH (mU/l) 4.2 (1.1–8.4) 6.2 (3.1–16.4) 5.7 (2.2–15.6) 0.609
IGF1 (ng/ml) 223 (147–436) 403 (252–663) 310 (194–582) 0.460
IGF1 Z-score 2.1 (0.7–4.4) 5.1 (3.3–6.6) 4.5 (2.3–6.5) 0.002
Previous TSS, n (%) 14 (67) 10 (40) 14 (27) 0.008
Use of SSA, n (%) 11 (54) 19 (76) 35 (69) 0.222
Acromegaly controlled, n (%) 8 (38) 3 (12) 11 (22) 0.105
Data are given as absolute numbers (n) and percentage (%), meanGS.D. or median (interquartile range). SBP, systolic blood pressure; DBP, diastolic blood
pressure; GH, growth hormone; TSS, transsphenoidal surgery; SSA, somatostatin analogue; NGT, normal glucose tolerance; ECMDs, early carbohydrate

















Research A V Dreval et al. Diabetes in acromegaly 4–6 3 :96(14.3%, Table 1). When we analysed the results of the
OGTT performed in those not known to have diabetes, we
observed a higher prevalence of newly diagnosed diabetes
and ECMDs in patients with acromegaly compared with
both population-based screening groups (Table 2).
In Fig. 1, we show that there is a gradual increase in
diabetes prevalence with age in the general population and
in patients with acromegaly. In patients with acromegaly,
DM as well as all disturbances in glucose metabolism is
moreprevalentwhencomparedwith thegeneralpopulation
in all age groups. Only 28.8% of patients with acromegaly
were proved to have normal glucose tolerance (NGT).
Table 3 lists the differences in clinical and biochemical
characteristics in patients with acromegaly according to
disturbances in glucose metabolism. Subjects with ECMDs
and diabetes were older and more obese, and the diabetes
group had the highest proportion of women. The duration
of acromegaly was longest in the diabetes group, and IGF1
levels were higher in subjects with ECMDs and diabetes
than in individuals with NGT. When we looked at the
different age groups, we found the duration of clinical
symptoms to be longer in the oldest subjects (those
O60 years) than in subjects in the age group of 20–40
years (median 16.7 vs 8.0 years, P!0.01).Table 4 Odds ratios for the presence of ECMDs and DM in patien
Parameters NGT ECMD
Age (per S.D.) 1.0 1.10 (0.43–
BMI (per S.D.) 1.0 1.73 (0.58–
IGF1 Z-score 1.0 1.58 (1.09–
Data are given as ORs with 95% CI, adjusted for age, BMI, duration of acro
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Published by Bioscientifica LtdLogistic regression analysis showed that the presence
of glucose derangement was predicted by age, BMI and
levels of IGF1. The odds of an acromegaly patient
progressing to ECMDs or diabetes for each of these
parameters are depicted in Table 4.
Discussion
In this paper, we have described a high prevalence of DM
and ECMDs in patients with acromegaly. Over 50% of
our patients had DM, either overt and already being
treated with diet or medication or diagnosed with an
OGTT during our study. In a further 26% of subjects, the
OGTT revealed the presence of IFG or IGT, together named
ECMDs. The prevalence of both DM and ECMDs was
significantly higher in patients with acromegaly than
in the general population or in a population with a
high risk of diabetes; only 22% of subjects with acro-
megaly were normoglycaemic. This report on glucose
metabolism derangements in a large population of
patients with acromegaly in Russia confirms earlier reports
demonstrating the prevalence of ECMDs to be higher in
these patients than in the general population (2, 5, 6, 7).
In accordance with these earlier observations, we
observed those patients who had already developedts with acromegaly.
s DM ECMDsCDM
2.82) 2.74 (1.11–6.8)* 1.98 (0.86–4.5)
5.2) 3.26 (1.14–9.3)* 2.70 (0.98–7.4)
2.27)* 1.50 (1.06–2.11)* 1.48 (1.07–2.06)*
megaly, fasting growth hormone levels, IGF1 Z-score and treatment with
CMDs, early carbohydrate metabolism disorders; DM, diabetes mellitus.
This work is licensed under a Creative Commons

















Research A V Dreval et al. Diabetes in acromegaly 5–6 3 :97diabetes or ECMDs to be older and have a higher BMI, and
a longer duration of acromegaly. In addition, our logistic
regression models showed that age, BMI and levels of IGF1
were independently associated with the presence of
ECMDs and DM. Our finding that levels of IGF1, but not
levels of GH, could predict abnormal glucose metabolism
is partly in accordance with the observations of others.
These two risk factors have been assessed in several studies
(2, 5, 6, 7), but the results were conflicting. A Polish
study in 220 treatment-naı¨ve patients with acromegaly
reported no significant differences in basal plasma GH,
IGF1 or fasting insulin concentrations between normo-
glycaemic patients and those with impairments in glucose
tolerance (6), although the latter group of patients was
significantly older. With regard to IGF1, a recent paper
reported that higher IGF1 levels were associated withmore
severe insulin resistance and hyperglycaemia (12). In
accordance with the data of Colao et al. (14), the presence
of DM was associated with a higher age and longer disease
duration, and in addition IGF1 levels predicted fasting as
well as 2 h glucose levels and HbA1c after 12 months of
SSA treatment. The effects of GH and IGF1 on glucose
metabolism are complex. On the one hand, GH hyperse-
cretion leads to an increase in insulin resistance (decrease
in glucose uptake and glycolysis and increase in avail-
ability of free fatty acids) in adipose tissue and muscles,
and to an increase in gluconeogenesis in hepatocytes (21),
and indeed, a significant correlation between plasma GH
and IGF1 concentrations and measures of insulin resist-
ance has been reported (6). On the other hand, IGF1 has
a positive effect on hybrid insulin/IGF1 receptors in
adipose tissue, muscles and hepatocytes, which ensures
its insulin-like action (21). IGF1-dependent gastric inhibi-
tory polypeptide (GIP) secretion additionally stimulates
insulin secretion (22). IGF1 also increases the sensitivity
of hepatocytes to the effects of GH (21, 23), which are
diabetogenic as mentioned above. An additional anti-
diabetogenic effect may be exerted by somatostatin
analogues, which decrease GH hypersecretion, and long-
acting octreotide in particular has been associated with
a better control of IGF1 (24). Nevertheless, these medi-
cations appear to decrease insulin secretion.
A final important finding was that patients who
had undergone TSS had a lower prevalence of glucose
derangements: the percentage of patients with NGT was
three times higher in the group that had undergone TSS.
However, in regression analysis, previous TSS was not
an independent predictor of glucose derangements,
probably because those who had undergone TSS hadhttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0021
 2014 The authors
Published by Bioscientifica Ltda mean age 8 years younger than those who had not
undergone surgery.
We conclude that disturbances of glucose metabolism
frequently develop in patients with acromegaly. The
prevalence of DM and ECMDs among patients with
acromegaly considerably exceeds the prevalence of T2DM
and ECMDs in the general population and in a high-risk
population. Its development depends on age, BMI and
IGF1 levels.
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